Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, fo...

Full description

Bibliographic Details

Main Authors:	Saußele, Susanne (Author) , Hehlmann, Rüdiger (Author) , Fabarius, Alice (Author) , Rinaldetti, Sébastien (Author) , Kohlbrenner, Katharina (Author) , Hofmann, Wolf-Karsten (Author) , Müller, Martin Christian (Author)
Format:	Article (Journal)
Language:	English
Published:	26 February 2018
In:	Leukemia Year: 2018, Volume: 32, Issue: 5, Pages: 1222-1228
ISSN:	1476-5551
DOI:	10.1038/s41375-018-0055-7
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41375-018-0055-7 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41375-018-0055-7
Author Notes:	Susanne Saussele, Rüdiger Hehlmann, Alice Fabarius, Sabine Jeromin, Ulrike Proetel, Sebastien Rinaldetti, Katharina Kohlbrenner, Hermann Einsele, Christiane Falge, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, Elisabeth Oppliger Leibundgut, Dominik Heim, Stefan W. Krause, Wolf-Karsten Hofmann, Joerg Hasford, Markus Pfirrmann, Martin C. Müller, Andreas Hochhaus, Michael Lauseker